Dermatologic Complications | Regenecare® Wound Gel in Treating Rash in Patients Receiving Cetuximab or Other Epidermal Growth Factor Receptor Inhibitor Therapy for Cancer

Dermatologic Complications research study

What is the primary objective of this study?

RATIONALE: Regenecare® wound gel may help relieve pain and itching in patients who develop an acne-like rash while undergoing treatment with cetuximab or another epidermal growth factor receptor inhibitor for cancer. PURPOSE: This clinical trial is studying how well Regenecare® wound gel works in treating rash in patients receiving cetuximab or another epidermal growth factor receptor inhibitor therapy for cancer.

Who is eligible to participate?

DISEASE CHARACTERISTICS: - Diagnosis of cancer - Starting treatment with cetuximab or other EGFR inhibitor (e.g., erlotinib hydrochloride) on another clinical trial PATIENT CHARACTERISTICS: - Not pregnant or nursing - No known history of hypersensitivity to amine-type local anesthetics or to other components of MPM Regenecare® wound gel - No other concurrent, serious skin disorders (i.e., scleroderma or psoriasis) that would interfere with assessment of EGFR inhibitor-induced rash PRIOR CONCURRENT THERAPY: - See Disease Characteristics - No other concurrent topical facial creams or lotions

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Dermatologic Complications

Unspecified Adult Solid Tumor, Protocol Specific

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Dietary Supplement:collagen/aloe vera/vitamin E/lidocaine topical hydrogel

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

Study Status

Unknown status

Start Date: July 2006

Completed Date:

Phase: N/A

Type: Interventional


Primary Outcome: Efficacy of Regenecare® wound gel, in terms of alleviating pain and itching

Secondary Outcome: Efficacy of Regenecare® wound gel, in terms of reducing severity, redness, and appearance of rash

Study sponsors, principal investigator, and references

Principal Investigator: Mark F. Kozloff, MD

Lead Sponsor: Ingalls Memorial Hospital


More information:

Discuss Rash